Business Wire, Oct. 23, 2006 Sepracor today announced that it presented data from a Phase III trial of BROVANA(TM) Inhalation Solution at the annual meeting of the American College of Chest Physicians in Salt Lake City. The study evaluated airway function over a period of 12 weeks in patients with COPD. "In this study, treatment with nebulized BROVANA resulted in rapid bronchodilation and maintenance improvement, providing beneficial effects for patients with COPD," said William J. Calhoun M.D., Sealy and Smith Distinguished Professor of Internal Medicine; Director, Division of Allergy, Pulmonary, Immunology, CCM, and Sleep at the University of Texas Medical Branch, Galveston.